LifeSignals Receives CE Mark Approval For LifeSignals ECG Remote Monitoring Biosensor Platform (LX1250E)


Continuous patient monitoring with remote data access in ambulatory, hospital and home settings enables faster clinical decision making

FREMONT, Calif.- LifeSignals, today announced the awarding of the CE (Conformité Européene) Mark for their LifeSignals ECG Remote Monitoring Biosensor – a disposable wireless remote monitoring system, intended for use by healthcare professionals for continuous collection of Electrocardiography (ECG) and Heart Rate monitoring in ambulatory, hospital, healthcare and home settings.

For the first time, patient data can be transmitted wirelessly throughout the care continuum with high reliability from the LifeSignals Biosensor, to a secure cloud-based platform. Healthcare professionals can remotely access this data and rapidly make treatment decisions independent of patient location. The interoperable device can be integrated into most clinical workflows, including Remote Patient Monitoring systems, Mobile Cardiac Telemetry systems, Holter and Event Monitoring Systems.

“This CE Mark approval of LifeSignals’ next generation wireless technology-based biosensor, represents a major step forward in our drive to “untether” patient monitoring systems,,” said Surendar Magar, co-founder and CEO of LifeSignals. “With the integration of the LifeSignals Biosensor, clinically-accurate patient data can be captured inexpensively and sent to existing medical monitoring systems or cloud-based systems for direct analysis. Healthcare professionals can make faster treatment decisions while patients can be confident of receiving data-driven personalized therapy”

The LifeSignals Biosensor has several unique features:

Three-day data capture of two-channel ECG and Heart Rate data for enhanced patient diagnosis

Single use device that reduces infection control concerns and operational costs

Lightweight and splash-proof for improved patient comfort and compliance

Proprietary patented single-chip LC1100 LifeSignals Processor platform, allowing secure detection, storage and transmission of patient data even in ‘noisy’ multi-patient hospital environments

The LifeSignals Biosensor will be sold as a white-labeled device, marketed in Europe through a network of partnerships from OEMs and telehealth software providers to specialist hospital facilities. The biosensor is available immediately to interested partners. LifeSignals has also developed a cloud-based Holter Analysis platform, incorporating the use of LifeSignals biosensors, to facilitate the expansion of clinical remote ECG monitoring services.

About LifeSignals, Inc.
LifeSignals (formerly HMicro Inc.) is the Silicon Valley based creator and producer of the patented LifeSignals Processor, a semiconductor platform designed to faithfully capture and communicate vital life signals from humans and animals to the cloud. LifeSignals is a venture capital backed, fabless semiconductor company, enabled by equity investments from Flex, Uniquest, Dreamtech, Renew Group, Seraph Capital, Xseed Capital, and Reddy Capital. Further information can be found at


Kim Ramessa
Marketing and Communications Director
LifeSignals Group
M: +44 (0) 7425 316305


Richard Hayhurst
M: +44 (0) 7711 821527